NCT05737121: Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS |
|
|
| Recruiting | 2 | 120 | US | VNX001, Alkalinized lidocaine HCl and heparin sodium, Placebo, Placebo (for VNX001), Lidocaine, Alkalinized lidocaine HCl, Heparin, Alkalinized heparin sodium | Vaneltix Pharma, Inc., Prevail Infoworks, Inc | Interstitial Cystitis, Bladder Pain Syndrome | 05/24 | 05/24 | | |
NCT06394830: Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) |
|
|
| Not yet recruiting | 2 | 50 | NA | VNX001 | Vaneltix Pharma, Inc., Prevail Infoworks, Inc | Interstitial Cystitis, Bladder Pain Syndrome | 06/25 | 06/25 | | |
